TRYPHAENA was a randomized phase 2 study comparing TCbHP (6 cycles) and FEC (3 cycles) followed by THP (3 cycles) as neoadjuvant therapy in patients with HER2 + early breast cancer (n = 225). Here, ERBB2 is linked to breast carcinoma.